
Merck Animal Health receives EU CVMP positive opinion for NUMELVI

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
Merck (MRK) as a Reliable Dividend Player in the Dogs of the Dow Lineup
Merck & Co., Inc. (NYSE:MRK) is included among the 11 Dogs of the Dow Dividend Stocks to Buy Now. A close-up of a person's hand holding a bottle of pharmaceuticals. Merck & Co., Inc. (NYSE:MRK) has faced stock pressure due to its reliance on Keytruda but is diversifying. On July 9, Merck announced it would acquire UK biotech Verona Pharma for $10 billion, adding Ohtuvayre, a promising COPD treatment approved last year, to its portfolio. Ohtuvayre has had a strong launch and is being studied for more uses. Some analysts predict its sales could reach $4 billion, potentially making it another blockbuster for Merck. In its first quarter earnings, Merck & Co., Inc. (NYSE:MRK) highlighted that it began the year with strong progress, driven by growing contributions from its recently commercialized medicines and vaccines, along with ongoing advancements in its pipeline. It is focused and determined to fully capitalize on near-term opportunities while swiftly advancing the next wave of innovations that will improve patient outcomes and create long-term value for all stakeholders. Merck & Co., Inc. (NYSE:MRK) is also popular because of its dividend growth history, which spans 16 consecutive years. Currently, the company offers a quarterly dividend of $0.81 per share and has a dividend yield of 3.82%, as of July 26. While we acknowledge the potential of MRK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
3 days ago
- Yahoo
Rising Infertility, Medical Advances, Government Supports and Societal Shifts Driving Growth
The Saudi Arabia IVF market is projected to grow from $306.59 million in 2024 to $522.39 million by 2033, driven by a 6.10% CAGR. Factors like rising infertility rates, delayed parenthood, technological advancements, and supportive government initiatives contribute to this growth. The market segments into procedure types, instruments, and end-users. Notable players include FUJIFILM Holdings and Merck & Co. Despite growth, challenges like high treatment costs and cultural sensitivities persist. Recent advancements, such as the discovery by King Faisal Specialist Hospital & Research Centre, underscore ongoing innovations in the field. Saudi Arabian IVF Market Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia IVF Market Outlook 2025-2033" report has been added to Arabia IVF Market is expected to reach US$ 522.39 million by 2033 from US$ 306.59 million in 2024, with a CAGR of 6.10% from 2025 to 2033 Increasing infertility rates, increased awareness, delayed parenthood, reproductive technology improvements, supportive government policies, increased medical tourism, higher disposable incomes, higher healthcare investments, improved healthcare infrastructure, and shifting cultural perceptions towards fertility treatments are some of the drivers of the Saudi Arabian IVF market. When it is difficult to conceive naturally, couples or individuals may have the medical procedure of in vitro fertilization (IVF) done to help conceive. To create an embryo, an egg and a sperm are joined outside the body in a laboratory. After fertilization, the resulting embryo is monitored before it is inserted into the woman's uterus in hopes of potential implantation and pregnancy. IVF is often employed to treat infertility caused by issues such as male infertility, blocked fallopian tubes, or unexplained infertility. To enhance the chances of a healthy pregnancy, the treatment may additionally include genetic testing, hormone therapy, egg harvesting, and freezing IVF market in Saudi Arabia is growing considerably owing to a variety of converging factors. Stress, lifestyle changes, and the rising age of first-time mothers are significant reasons for the high rates of infertility. Second, due to shifting social values and greater awareness of IVF options, there is greater societal acceptance of assisted reproduction. Treatment is becoming more appealing with greater success rates introduced by advances in technology such as genetic screening, freezing embryos, and intracytoplasmic sperm injection (ICSI). Market access is also supplemented by government initiatives, including subsidies and supportive healthcare legislation. In addition, Saudi Arabia's attempts to boost its medical tourism sector and enhance its health infrastructure cement its position as a regional hub for advanced reproductive Drivers for the Saudi Arabia IVF Market Delayed ParenthoodDelayed parenthood is one of the key drivers fueling the Saudi Arabian IVF market's growth. The first-time parents' average age keeps rising because more individuals and couples tend to prioritize their education, careers, and financial stability before having children. Delaying childbearing naturally reduces fertility, rendering IVF and other reproductive technologies more essential. This trend is being driven by changing social norms and greater acceptance of working women in Saudi Arabia. Lower reproduction rates are further linked to lifestyle and delayed marriages. Infertility treatments are increasingly being sought after with delayed motherhood gaining pace. IVF offers an effective solution, driving market growth as more people seek effective, scientifically validated solutions to age-related AdvancementsThe Saudi Arabian IVF industry is growing largely because of technological advancements. Intracytoplasmic sperm injection (ICSI), preimplantation genetic testing (PGT), and embryo vitrification are some of the advanced reproductive technologies that have increased IVF success rates significantly and made them more reliable and accessible. Couples who are facing problems with infertility are increasingly interested in these advances. To further expand its presence in the region, Burjeel Holdings PLC, a leading provider of super-specialty healthcare services, made plans in September 2024 to introduce IVF services in Saudi Arabia. Their Trust Fertility Clinic at Burjeel Medical City (BMC) will integrate with gynecology, fetal medicine, and pediatric subspecialties and IVF. BMC provides women with a seamless, superior reproductive experience from conception through birth in one, cutting-edge facility by offering full mother and baby care through specialized NICU and PICU SupportThe growth of the IVF market in Saudi Arabia is largely attributed to government support, which aligns with the Saudi Vision 2030 objectives of enhancing the quality and availability of healthcare. The government has entrusted the licensing and regulation of fertility clinics to the Ministry of Health, ensuring that the requirements of safety and effectiveness are fulfilled. To reduce economic burdens and provide better access to care, the government also offers funded help for IVF procedures to qualified individuals. The IVF sector has been further encouraged through massive investments in health infrastructure, including the development of advanced fertility centers. These programs combined create a friendly environment for individuals in need of fertility treatments, which stimulates market growth and positions Saudi Arabia as a front runner in the field for reproductive in the Saudi Arabia IVF Market Cultural and Religious SensitivitiesThe Saudi Arabian IVF market faces considerable obstacles due to cultural and religious sensitivity. In a culture steeped in Islamic customs, several forms of assisted reproduction, such surrogacy or third-party gamete donation, are typically forbidden by Islamic law. Compared to other nations, these limitations restrict the variety of IVF therapies that are available. Furthermore, frank conversations regarding infertility may be discouraged by conservative social norms, which could cause stigma and emotional hardship, particularly for women. Access to care is further diminished when people are reluctant to seek treatment out of fear of criticism or social pressure. Campaigns for culturally sensitive education and awareness are necessary to overcome these Treatment CostsIn the Saudi Arabian IVF industry, high treatment costs are a significant obstacle that prevents many couples from accessing fertility services. Because of the sophisticated equipment, skilled personnel, and numerous treatment cycles that are frequently necessary for success, IVF procedures can be costly. Although there is some government assistance, it is not very extensive, and many private insurance policies do not cover infertility treatments. Consequently, families with lower and intermediate incomes might find it difficult to pay for care, which could cause treatment to be postponed or stopped. These financial constraints highlight the need for more comprehensive insurance coverage and reasonably priced treatment options because they not only limit access but also heighten emotional stress. Key Players Analysis: Company Overview, Key Persons, Recent Development & Strategies, Sales Analysis FUJIFILM Holdings Corporation Hamilton Thorne Ltd. Vitrolife AB Thermo Fisher Scientific, Inc. Bayer AG Merck & Co., Inc. Boston IVF Fortis Healthcare Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $306.59 Million Forecasted Market Value (USD) by 2033 $522.39 Million Compound Annual Growth Rate 6.1% Regions Covered Saudi Arabia Key Topics Covered: 1. Introduction2. Research & Methodology2.1 Data Source2.1.1 Primary Sources2.1.2 Secondary Sources2.2 Research Approach2.2.1 Top-Down Approach2.2.2 Bottom-Up Approach2.3 Forecast Projection Methodology3. Executive Summary4. Market Dynamics4.1 Growth Drivers4.2 Challenges5. Saudi Arabia IVF Market5.1 Historical Market Trends5.2 Market Forecast6. Market Share Analysis6.1 By Procedure Type6.2 By Instrument6.3 By Surgery6.4 By End Users7. Procedure Type7.1 Fresh non-donor7.2 Frozen non-donor7.3 Fresh Donor7.4 Frozen Donor8. Instrument8.1 Disposable Devices8.2 Culture Media8.3 Equipment9. Surgery9.1 Embryo Culture Media9.2 Cryopreservation Media9.3 Sperm Processing Media9.4 Ovum Processing Media10. End Users10.1 Fertility Clinics10.2 Hospitals & Other Setting11. Porter's Five Forces Analysis11.1 Bargaining Power of Buyers11.2 Bargaining Power of Suppliers11.3 Degree of Competition11.4 Threat of New Entrants11.5 Threat of Substitutes12. SWOT Analysis12.1 Strength12.2 Weakness12.3 Opportunity12.4 Threats13. Key Players Analysis For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian IVF Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Bloomberg
3 days ago
- Bloomberg
Lilly Gets Limited European Backing for Alzheimer's Disease Drug
Eli Lilly & Co. won the backing of European Union regulators for its Alzheimer's disease drug Kisunla in a specific group of patients, potentially paving the way for it to become the second drug in the region to slow the most common cause of dementia in the elderly. The European Medicines Agency 's drug advisory panel recommended granting a marketing authorization for Kisunla in patients who don't carry a specific gene that can increase the risk of a potentially fatal brain-swelling condition called ARIA. In the US, the medicine is approved for a much wider group of patients. The EU previously approved a similar medicine from Eisai Co. and Biogen Inc called Leqembi though its use was also limited to patients at lower risk for brain swelling.